Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats

Synapse

Volumn 50, Issue 1, 2003, Pages 20-28

  Bruijnzeel, Adrie W ^a   Arkou, Athina M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antidepressant; Bupropion; Nicotine; Rat; Reward; Self administration

Indexed keywords

AMFEBUTAMONE; NICOTINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SELF ADMINISTRATION; FOOD INTAKE; MALE; MOTIVATION; NEUROPHARMACOLOGY; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; RAT; REINFORCEMENT; TRAINING;

ANIMALS; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EATING; FEEDING BEHAVIOR; MALE; NICOTINE; RATS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); REWARD; SELF ADMINISTRATION; TOBACCO USE DISORDER;

EID: 0042421957     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10242     Document Type: Article

References (66)

1. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. 2002. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 288:468-474.
2. Arnold JM, Roberts DC. 1997. A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57:441-447.
3. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F. 1995. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401.
4. Bardo MT, Green TA, Crooks PA, Dwoskin LP. 1999. Nornicotine is self-administered intravenously by rats. Psychopharmacology (Berl) 146:290-296.
5. Benwell ME, Balfour DJ. 1997. Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur J Pharmacol 325:13-20.
6. Brazell MP, Mitchell SN, Gray JA. 1991. Effect of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats: a dose-response and antagonist study. Neuropharmacology 30:823-833.
7. Caine SB, Lintz GF, Koob GF. 1993. Intravenous drug-self-administration techniques in animals. In: Saghal A, editor. Behavioural neuroscience: a practical approach. New York: Oxford University Press. p 117-143.
8. Cooper BR, Hester TJ, Maxwell RA. 1980. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215:127-134.
9. Correa M, Carlson BB, Wisniecki A, Salamone JD. 2002. Nucleus accumbens dopamine and work requirements on interval schedules. Behav Brain Res 137:179-187.
10. Corrigall WA, Coen KM. 1989. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 99:473-478.
11. Corrigall WA, Coen KM. 1991. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl) 104:171-176.
12. Corrigall WA, Coen KM, Adamson KL. 1994. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653:278-284.
13. Corrigall WA, Coen KM, Adamson KL, Chow BL, Zhang J. 2000. Response ofnicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl) 149:107-114.
14. Corrigall WA, Coen KM, Zhang J, Adamson KL. 2001. GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology (Berl) 158:190-197.
15. Crooks PA, Dwoskin LP. 1997. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 54:743-753.
16. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. 2003. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (in press).
17. David DJ, Renard CE, Jolliet P, Hascoet M, Bourin M. 2003. Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology (Berl) 166:373-382.
18. Donny EC, Caggiula AR, Knopf S, Brown C. 1995. Nicotine self-administration in rats. Psychopharmacology (Berl) 122:390-394.
19. Donny EC, Caggiula AR, Mielke MM, Booth S, Gharib MA, Hoffman A, Maldovan V, Shupenko C, McCallum SE. 1999. Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 147:135-142.
20. Drew AE, Derbez AE, Werling LL. 2000. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 38:10-16.
21. Fattore L, Cossu G, Martellotta MC, Fratta W. 2002. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol 37:495-498.
22. Fryer JD, Lukas RJ. 1999. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88-92.
23. Fu Y, Matta SG, Brower VG, Sharp BM. 2001. Norepinephrine secretion in the hypothalamic paraventricular nucleus of rats during unlimited access to self-administered nicotine: an in vivo microdialysis study. J Neurosci 21:8979-8989.
24. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR. 2002. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 52:53-61.
25. Glick SD, Maisonneuve IM, Kitchen BA. 2002. Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha3beta4 nicotinic receptors. Eur J Pharmacol 448:185-191.
26. Glover ED, Glover PN. 2001. Pharmacologic treatments for the nicotine dependent smoker. Am J Health Behav 25:179-182.
27. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD. 2001. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med 135:423-433.
28. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. 1999. Recent advances in the pharmacotherapy of smoking. JAMA 281:72-76.
29. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202.
30. Johnston AJ, Ascher J, Leadbetter R, Schmith VD, Patel DK, Durcan M, Bentley B. 2002. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs 62(Suppl 2):11-24.
31. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. 1999. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685-691.
32. Koob GF, Sanna PP, Bloom FE. 1998. Neuroscience of addiction. Neuron 21:467-476.
33. Li SX, Perry KW, Wong DT. 2002. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42:181-190.
34. Malin DH. 2001. Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav 70:551-559.
35. Mansbach RS, Chambers LK, Rovetti CC. 2000. Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine. Psychopharmacology (Berl) 148:234-242.
36. Mansvelder HD, Keath JR, McGehee DS. 2002. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33:905-919.
37. Markou A, Paterson NE. 2001. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res 3:361-373.
38. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF. 1993. Animal models of drug craving. Psychopharmacology (Berl) 112:163-182.
39. McGregor A, Roberts DC. 1993. Dopaminergic antagonism within the nucleus accumbens or the amygdala produces differential effects on intravenous cocaine self-administration under fixed and progressive ratio schedules of reinforcement. Brain Res 624:245-252.
40. Mitchell SN, Smith KM, Joseph MH, Gray JA. 1993. Increases in tyrosine hydroxylase messenger RNA in the locus coeruleus after a single dose of nicotine are followed by time-dependent increases in enzyme activity and noradrenaline release. Neuroscience 56:989-997.
41. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. 1989. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2:273-279.
42. Nowend KL, Arizzi M, Carlson BB, Salamone JD. 2001. D1 or D2 antagonism in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but leads to compensatory increases in chow consumption. Pharmacol Biochem Behav 69:373-382.
43. Parkinson J, Fudge J, Hurd Y, Pennartz C, Peoples L. 2000. Finding motivation at Seabrook Island: the ventral striatum, learning and plasticity. Trends Neurosci 23:383-384.
44. Paterson NE, Markou A. 2002. Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat. Synapse 44:252-253.
45. Paterson NE, Semenova S, Gasparini F, Markou A. 2003. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 167:257-264.
46. Piacentini MF, Clinckers R, Meeusen R, Sarre S, Ebinger G, Michotte Y. 2003. Effect of bupropion on hippocampal dopamine, serotonin and noradrenaline and on peripheral hormonal concentrations in the rat: an in vivo study. J Appl Physiol (in press).
47. Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT. 2002. Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 303:664-672.
48. Salamone JD, Correa M. 2002. Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137:3-25.
49. Schilstrom B, Nomikos GG, Nisell M, Hertel P, Svensson TH. 1998. N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82:781-789.
50. Shanks N, Anisman H. 1989. Strain-specific effects of antidepressants on escape deficits induced by inescapable shock. Psychopharmacology (Berl) 99:122-128.
51. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J. 2000. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33-40.
52. Shoaib M, Schindler CW, Goldberg SR. 1997. Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) 129:35-43.
53. Shoaib M, Sidhpura N, Shafait S. 2002. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl) 165:405-412.
54. Slemmer JE, Martin BR, Damaj MI. 2000. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327.
55. Stolerman IP, Jarvis MJ. 1995. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 117:2-10.
56. Sullivan MA, Covey LS. 2002. Nicotine dependence: the role for anti-depressants and anxiolytics. Curr Opin Invest Drugs 3:262-271.
57. Svensson TH, Engberg G. 1980. Effect of nicotine on single cell activity in the noradrenergic nucleus locus coeruleus. Acta Physiol Scand Suppl 479:31-34.
58. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B. 2001. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357:1571-1575.
59. Twombly R. 2002. World Health Organization takes on 'tobacco epidemic.' J Natl Cancer Inst 94:644-646.
60. Valentine JD, Hokanson JS, Matta SG, Sharp BM. 1997. Self-administration in rats allowed unlimited access to nicotine. Psychopharmacology (Berl) 133:300-304.
61. Watkins SS, Epping-Jordan MP, Koob GF, Markou A. 1999. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62:743-751.
62. Watkins SS, Koob GF, Markou A. 2000. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2:19-37.
63. Wellman PJ. 2000. Norepinephrine and the control of food intake. Nutrition 16:837-842.
64. Wiley JL, Lavecchia KL, Martin BR, Damaj MI. 2002. Nicotine-like discriminative stimulus effects of bupropion in rats. Exp Clin Psychopharmacol 10:129-135.
65. Wise RA. 2002. Brain reward circuitry: insights from unsensed incentives. Neuron 36:229-240.
66. Young R, Glennon RA. 2002. Nicotine and bupropion share a similar discriminative stimulus effect. Eur J Pharmacol 443:113-118.